S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Latest freight railroad layoffs and Wall Street pressure renew concerns about safety and service
Critical asset just had biggest fall on record (Ad)
One year after buying a failed bank, New York Community Bancorp is struggling
Dell, NetApp rise; Ginkgo Bioworks, New York Community Bancorp fall, Friday, 3/1/2024
Critical asset just had biggest fall on record (Ad)
How major US stock indexes fared Friday, 3/1/2024
China pledges to increase opportunities for foreign companies as it seeks to boost its economy
Critical asset just had biggest fall on record (Ad)
Brazil's economy grows 2.9% in Lula's 1st year, beating expectations
A US appeals court ruling could allow mine development on Oak Flat, land sacred to Apaches
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Latest freight railroad layoffs and Wall Street pressure renew concerns about safety and service
Critical asset just had biggest fall on record (Ad)
One year after buying a failed bank, New York Community Bancorp is struggling
Dell, NetApp rise; Ginkgo Bioworks, New York Community Bancorp fall, Friday, 3/1/2024
Critical asset just had biggest fall on record (Ad)
How major US stock indexes fared Friday, 3/1/2024
China pledges to increase opportunities for foreign companies as it seeks to boost its economy
Critical asset just had biggest fall on record (Ad)
Brazil's economy grows 2.9% in Lula's 1st year, beating expectations
A US appeals court ruling could allow mine development on Oak Flat, land sacred to Apaches
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Latest freight railroad layoffs and Wall Street pressure renew concerns about safety and service
Critical asset just had biggest fall on record (Ad)
One year after buying a failed bank, New York Community Bancorp is struggling
Dell, NetApp rise; Ginkgo Bioworks, New York Community Bancorp fall, Friday, 3/1/2024
Critical asset just had biggest fall on record (Ad)
How major US stock indexes fared Friday, 3/1/2024
China pledges to increase opportunities for foreign companies as it seeks to boost its economy
Critical asset just had biggest fall on record (Ad)
Brazil's economy grows 2.9% in Lula's 1st year, beating expectations
A US appeals court ruling could allow mine development on Oak Flat, land sacred to Apaches
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Latest freight railroad layoffs and Wall Street pressure renew concerns about safety and service
Critical asset just had biggest fall on record (Ad)
One year after buying a failed bank, New York Community Bancorp is struggling
Dell, NetApp rise; Ginkgo Bioworks, New York Community Bancorp fall, Friday, 3/1/2024
Critical asset just had biggest fall on record (Ad)
How major US stock indexes fared Friday, 3/1/2024
China pledges to increase opportunities for foreign companies as it seeks to boost its economy
Critical asset just had biggest fall on record (Ad)
Brazil's economy grows 2.9% in Lula's 1st year, beating expectations
A US appeals court ruling could allow mine development on Oak Flat, land sacred to Apaches
NASDAQ:SNSS

Sunesis Pharmaceuticals (SNSS) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
N/A
50-Day Range
$2.38
$5.32
52-Week Range
N/A
Volume
1.20 million shs
Average Volume
4.33 million shs
Market Capitalization
$96.26 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

SNSS stock logo

About Sunesis Pharmaceuticals Stock (NASDAQ:SNSS)

Sunesis Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of targeted inhibitors for the treatment of hematologic and solid cancers. Its lead product candidate is vecabrutinib, a non-covalent inhibitor of Bruton's tyrosine kinase (BTK), which is in Phase 1b/2 clinical trial for the treatment of chronic lymphocytic leukemia, mantle cell lymphoma, and other B-cell malignancies. The company is also developing SNS-510, which is in preclinical pharmacology studies for the treatment of solid tumor and hematologic malignancies; various other partnered programs, such as TAK-580, a pan-Raf inhibitor program that is in Phase 1 clinical trial for the treatment of pediatric low-grade glioma; and vosaroxin, an anti-cancer quinolone derivative that intercalates DNA and inhibits topoisomerase II. It has a collaboration agreement with Biogen Idec MA, Inc. to discover, develop, and commercialize small molecule BTK inhibitors; and license agreement with Takeda Pharmaceutical Company Limited to develop and commercialize preclinical inhibitors of PDK1. Sunesis Pharmaceuticals, Inc. was founded in 1998 and is headquartered in South San Francisco, California.


SNSS Stock News Headlines

AQSZF Aequus Pharmaceuticals Inc.
4 Breakout Stocks to Watch Going Into Labor Day
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
4 Stocks Under $10 to Trade Now
See More Headlines
Receive SNSS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sunesis Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/15/2020
Today
3/02/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:SNSS
CUSIP
86732860
Fax
N/A
Employees
24
Year Founded
N/A

Profitability

Net Income
$-23,330,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$2.07 million
Book Value
$1.42 per share

Miscellaneous

Free Float
N/A
Market Cap
$96.26 million
Optionable
Optionable
Beta
2.27
Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

  • Dr. Judith A. Fox (Age 64)
    Chief Scientific Officer and Exec. VP of R&D
    Comp: $562.19k
  • Mr. Parvinder S. Hyare (Age 50)
    Interim CEO & Principal Exec. Officer
  • Ms. Tina Gullotta (Age 46)
    Principal Financial Officer, VP of Fin. & Principal Accounting Officer
  • Dr. Deborah A. Thomas
    Sr. VP, Regulatory Affairs, Quality Assurance & Pharmacovigilance
  • Mr. Daniel N. Swisher Jr. (Age 58)
    Strategic Advisor














SNSS Stock Analysis - Frequently Asked Questions

How were Sunesis Pharmaceuticals' earnings last quarter?

Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) issued its earnings results on Sunday, November, 15th. The biopharmaceutical company reported ($0.29) EPS for the quarter, beating analysts' consensus estimates of ($0.30) by $0.01.

When did Sunesis Pharmaceuticals' stock split?

Sunesis Pharmaceuticals shares reverse split on the morning of Thursday, September 3rd 2020. The 1-10 reverse split was announced on Wednesday, September 2nd 2020. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, September 2nd 2020. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What is Dan Swisher Jr.'s approval rating as Sunesis Pharmaceuticals' CEO?

4 employees have rated Sunesis Pharmaceuticals Chief Executive Officer Dan Swisher Jr. on Glassdoor.com. Dan Swisher Jr. has an approval rating of 82% among the company's employees.

What other stocks do shareholders of Sunesis Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Sunesis Pharmaceuticals investors own include Amarin (AMRN), QUALCOMM (QCOM), Actinium Pharmaceuticals (ATNM), NVIDIA (NVDA), VBI Vaccines (VBIV), Inovio Pharmaceuticals (INO), SCYNEXIS (SCYX), Exelixis (EXEL) and Novavax (NVAX).

This page (NASDAQ:SNSS) was last updated on 3/2/2024 by MarketBeat.com Staff